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any of these components results in the breakdown of this specialized multicellular structure and consequently
promotes neuroinﬂammation and neurodegeneration. In several high incidence pathologies such as stroke,
Alzheimer's (AD) and Parkinson's disease (PD) the BBB is impaired. However, even a damaged andmore perme-
able BBB can pose serious challenges to drug delivery into the brain. The use of nanoparticle (NP) formulations
able to encapsulate molecules with therapeutic value, while targeting speciﬁc transport processes in the brain
vasculature, may enhance drug transport through the BBB in neurodegenerative/ischemic disorders and target
relevant regions in the brain for regenerative processes. In this review,wewill discuss BBB composition and char-
acteristics and how these features are altered in pathology, namely in stroke, AD and PD. Additionally, factors
inﬂuencing an efﬁcient intravenous delivery of polymeric and inorganic NPs into the brain as well as NP-related
delivery systems with the most promising functional outcomes will also be discussed.
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The central nervous system (CNS) barriers are essential interfaces
between the CNS and the periphery. The most selective one is the
blood brain barrier (BBB), being mainly composed of endothelial cells
connected by tight junctions (TJs) and adherens junctions (AJs) [1]. In
some brain pathologies (e.g. brain infections, neurodegenerative disor-
ders, and stroke) the BBB is altered and becomes more permeable
allowing the entry of molecules that can induce inﬂammatory re-
sponses and neuronal damage [2].
In parallel, increasing worldwide lifespan has led to a rise in the
prevalence of stroke, Alzheimer's (AD) and Parkinson's disease (PD),
having a huge impact in society and the economy [3–5]. However, the
majority of current available treatments are symptomatic and unable
to restore quality of life and halt or ameliorate damage. Until now the
search for new therapies remains without signiﬁcant improvements,
and drug delivery – promising new molecules or even rehabilitating
old ones – is the major challenge to be overcome.
Nanoparticles (NPs) are considered one of the most auspicious and
versatile drug delivery systems into inaccessible regions like the brain,
being able to provide protection to therapeutic agents while efﬁciently
delivering them into the damaged areas. Several NP formulations have
been administered intravenously in healthy animals proving their efﬁ-
cacy in crossing the BBB, mainly when they are modiﬁed with surfac-
tants or ligands. With this in mind, it is important to understand BBB
modiﬁcations in pathology in order to take advantage of these traits to
develop new and innovative NP formulations capable of successfully
targeting damaged areas of the brain.
In this review, the alterations of the BBB in pathology, namely in
stroke, AD and PD, will be reviewed. The principal characteristics of
NPs that allow efﬁcient brain delivery as well as targeting of the disease
regions for repair will be covered.Fig. 1. Blood–brain barrier (BBB) composition and main alterations found in pathological cond
adherens and tight junctions (TJs), and a sparse layer of pericytes. A basement membrane
surveying microglia are also important mediators of BBB integrity in physiological condition
permeability. Increased matrix metalloproteinase (MMP) activity, higher reactive oxygen spe
oxide synthase (eNOS) or from microglia/macrophage cells — via inducible NOS (iNOS)) alon
basement membrane degradation, TJ disruption (namely in occludin, zonula occludens (Z
culminate in neuroinﬂammation, leukocyte recruitment and brain parenchyma invasion, neuro2. BBB, general concept and mechanisms of passage
The CNS has developed a series of barriers to protect itself from in-
vading pathogens, neurotoxic molecules and circulating blood cells.
These structures with diverse degrees of permeability include the
blood–cerebrospinal ﬂuid (CSF) barrier, the blood–brain barrier (BBB),
the blood–retinal barrier and the blood–spinal cord barrier [1]. Among
these, the BBB is the most extensive and exclusive. It is mainly com-
posed of tightly connected brain endothelial cells and a discontinuous
layer of pericytes. The cellular architecture of the BBB and key alter-
ations occurring in a pathological context are depicted in Fig. 1.
The cerebral endothelium has unique properties that allow it to
maintain BBB integrity, transendothelial transport of cells and angio-
genic capability to allow revascularization when needed [6,7]. To rein-
force the cohesiveness of the barrier, brain endothelial cells express
speciﬁc proteins, namely TJs and AJs [8]. TJs are constituted by trans-
membrane and cytoplasmic proteins that include claudins, occludin,
junction adhesion molecules (JAMs), zonula occludens (ZO) and acces-
sory proteins. Although there is a strong cohesive systemkeeping endo-
thelial cells tightly connected, the BBB sanctions the selective passage of
cells and small molecules to the brain.
The mechanism of passage between endothelial cells is named
paracellular, and is utilized for ions and solutes that depend on a gradi-
ent of concentration. The passage occurring through endothelial cells is
termed transcellular and the balance between paracellular–transcellu-
lar transport is decisive to deﬁne the degree of permeability in a healthy
BBB [9]. The transcellular pathway occurs in most cases with passive
diffusion of lipophilic molecules, which takes place through speciﬁc re-
ceptors to transport molecules such as carbon dioxide [6]. Proteins and
peptides, which are hydrophilic molecules, depend on a speciﬁc type of
transport to enter the brain, such as in the case of glucose transporter-1
(GLUT-1), which is responsible for glucose uptake, or speciﬁc receptorsitions. A) The BBB is mainly composed of vascular endothelial cells, highly connected by
and a layer of astrocyte end-foot processes surround the endothelium. Neurons and
s. B) In pathological conditions several BBB alterations occur culminating in increased
cies (ROS) and nitric oxide levels (derived from endothelial cells — via endothelial nitric
g with release of cytokines and chemokines by activated microglia/macrophages lead to
O)-1 and claudin 5 integrity) and an inﬂammatory response. Altogether these events
nal dysfunction and neurodegeneration.
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Other forms of transport occur via the formation of cellular invagina-
tions knownas caveolae. These structures formvesicles around themol-
ecule allowing the transport in or out of the brain. As described in the
next sections, transcytosis mechanisms occurring at BBB endothelial
cells are being currently explored as a way for transporting therapeutic
drugs into the brain (Fig. 2). However, the delivery of several of these
drugs to the brain parenchyma may also be reduced by ATP-binding
cassette transporters (ABCs), which are active efﬂux pumps that trans-
port possibly neurotoxic lipid-soluble molecules or other pharmaceutic
drugs into the blood [11]. A deeper knowledge regarding the mecha-
nisms of passage across this highly selective barrierwill foster thedevel-
opment of new strategies for the delivery of neuroprotective and
regenerative molecules that in normal conditions cannot pass the BBB.3. Other barriers and their role on neurogenic niches
Contrary to expectations, there are regions of the CNS that actually
beneﬁt from exposure to amore permissive barrier, such as the ventric-
ular and circumventricular areas of the brain. The ventricular system is
composed by four cavities: two lateral ventricles, and a third and fourth
ventricle whose choroid plexus and capillaries are responsible for the
production of CSF. Other important structures are the circumventricular
organs (CVOs) that line the third and fourth ventricle walls. These
highly vascularized structures have fenestrated capillaries and a weak
astrocytic contact that allows a direct exchange among the blood stream
and the brain parenchyma.Fig. 2. Blood–brain barrier (BBB) transportmechanisms for brain delivery of nanoparticles
(NPs). The BBB is highly selective and has speciﬁc transport mechanisms allowing a close
control of molecules/cells that enter the brain parenchyma. Loosened tight junctions (TJs)
allow the cross of NPs through the BBB, either by thepresence of a surfactant inNPs able to
disrupt the TJs or by BBB impairment due to pathological conditions. Receptor-mediated
transcytosis is the most common type of transport for NP entry into the brain. NPs can
be functionalized with different types of ligands (such as insulin, transferrin, lactoferrin
or antibodies against some endothelial receptors), or surfactants like polysorbate 80
(that adsorbs plasma proteins, namely apolipoprotein E enabling their binding to the
lipoprotein receptor-related proteins (LRPs)). The interaction between NP ligands and
respective receptors in the endothelial cell (luminal side) surface triggers plasma
membrane invaginations followed by pinch free forming vesicles, which facilitates the
release of the NPs in the opposite site of the membrane (parenchymal side). NPs coated
with molecules such as albumin or chitosan can cross the BBB by adsorptive
transcytosis. Efﬂux pumps may reduce the amount of NPs retained in brain parenchyma.One of the main neurogenic niches of the adult mammalian brain,
the subventricular zone (SVZ), located on thewalls of the lateral ventri-
cles, also relies on a more permissive vasculature [12]. The SVZ blood
vessels have deﬁned characteristics, namely areas that do not have
contacting astrocyte endfeet or pericytes, rendering it thinner and
more permeable [13]. Adjacent to the SVZ, the rostral migratory stream
(RMS), a highly vascularized area, comprises a demarcated route of
transit for newborn neurons in direct contact with the vasculature
[14]. Interestingly, there are studies that claim that new neurons can
also arise in CVO [15,16]. In a recent study, ischemic injury was induced
to stimulate the proliferation of stem cells in the SVZ and CVO. An in-
crease in both proliferation and differentiation was found not only in
these areas but also along the third and fourth ventricles [17]. All of
these brain areas share a common trait, a leaky BBB, which endows
them with a greater ability to perceive damage and to engage in brain
repair. Interestingly, recent studies have shown that intravenous injec-
tion of NPs, independently of their cargo and mechanism of transport
across the BBB, accumulate at high levels in these leaky regions.
For example, angiopep-conjugated poly(ethylene glycol)-copoly(ɛ-
caprolactone) nanoparticles (ANG-PEG-NPs; with a mean diameter of
around 90 nm) that were administered intravenously into healthy
mice passed through the BBB and accumulated in the ventricles, hippo-
campus and cortical layer. The ability of this formulation to accumulate
into speciﬁc areas can be an asset in the development of new therapeu-
tic strategies [18]. There are, therefore, strong evidences suggesting that
these brain regions which rely on a leaky BBB may provide an alterna-
tive route for NP entrance into the brain and, importantly, modulate
the regenerative ability of neural stem/progenitor cells. However, it
should be noted that these brain regionsmay mount other forms of ob-
struction to therapeutic drugs, by having increased enzymatic activity
(i.e. enzymatic barrier) in CVO.
4. Models to study NP transport through the BBB
In vitro BBB models offer interesting opportunities to study the up-
take, mechanism of transport, and cytotoxicity of NPs. In addition,
these models allow the performance of high-throughput screenings,
facilitate the manipulation of some parameters that affect BBB
(e.g. hypoxia, aglycemia, toxins, among others), reduce animal testing
and are less expensive than in vivo experiments. Models of BBB are
mostly based on endothelial cell cultures isolated from human [19,20]
or animal [21,22] sources. Nevertheless, in vitro BBB models based in
stem cells are also extensively used [23,24]. Endothelial cell mono-
cultures, produced in two-dimensions or three-dimensions, or co-
cultures of endothelial cells–astrocytes, endothelial cells–pericytes,
endothelial cells–pericytes–astrocytes to name a few, are some of the
examples. In the last years some in vitro BBB models that recapitulate
features of the BBB in stroke have been generated. For instance, Cho
and colleagues developed amicroﬂuidic platform based on rat brain en-
dothelial cells which showed increase in reactive oxygen species (ROS)
levels and decrease in ZO-1 expression upon oxygen and glucose depri-
vation, mimicking BBB dynamics in stroke. [25]. Additionally, in vitro
BBB models reproducing aspects of PD and AD BBB properties have
been also reported recently. A BBBmodel based in a co-culture of rat ce-
rebralmicrovessel endothelial cells isolated fromPD animals (chemical-
ly induced by 6-hydroxydopamine) with rat astroglial cells showed
signals of BBB dysfunction (P-gp overexpression, lower transelectrical
resistance) similar to the ones observed in vivo in 6-OHDA PD models,
being handy for drug delivery studies in PD [26]. A novel in vitro BBB
model based in the co-culture of porcine brain endothelial cells with a
human neuroblastoma cell line (SH-SY5Y) transfected with a luciferase
reporter vector coupled to an ADAM10-promoter (important to avoid
toxic cleavage of amyloid precursor protein) showed to be a versatile
tool to predict drug passage across the BBB in AD. Interestingly, this
model can be easily tuned to test drug delivery in other pathologies
[27]. Overall, these in vitro BBB models have been used to evaluate the
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oxidative stress, but not the permeation of NPs. Besides, it is important
to notice that: 1) inter-species differences in the concentration of trans-
porters and TJs may affect the ﬁnal readouts of themechanism of trans-
port [23,28]; 2) co-culture BBB models are superior to mono-culture
ones because they show improved barrier properties, preserve better
endothelial cell polarity and show increased expression of transporters
and TJs [29]; and 3) most studies have been performed with cells from
non-human sources and thus further advances are needed to produce
human models for better prediction of NP transport. Therefore, in vivo
models are essential to provide more insights into drug delivery across
the BBB due to their higher complexity and clinical relevance. NP
transport through the BBB is based mostly in in vivo animal models
and requires quantiﬁcation (e.g. inductively coupled plasma mass
spectrometry (ICP-MS) and neutron activation) and/or imaging (e.g.
ﬂuorescence microscopy, transmission electron microscopy (TEM))
techniques to monitor NP transport into the brain. Gold NPs are easily
quantiﬁable and monitored by ICP-MS and TEM [22,30–32] and have
been highly used to screen NP passage across the BBB in vivo. NPs can
be found in brain capillaries of mice and rats only 30 min after intrave-
nous administration [33,34]. These studies are in line with in vitro data
that report endothelial cell endocytosis as a relatively fast event with
NPs being observed after 30 min in the cell endolysosomal compart-
ment [19,35]. Sixty minutes after administration, NPs are observed
across the brain tissue [34]. According to several studies using different
NP formulations in mice models, the transport of NPs through the brain
peaks during the ﬁrst few hours (typically below 5 h), decreasing after-
wards [21,22,31,32,36]. Typically, the kinetics of transport is affected by
NP size and surface chemistry. The drawbacks of the current studies are
that, in most cases healthy animals have been used and no systematic
study has been performedwith animals at different development stages
or, in particular, with aged animals. Also, very few in vivo studies have
characterized NP transport in disease animal models for stroke, AD or
PD.
5. NPs for drug delivery into the brain
The development of new strategies to treat brain diseases is one of
the most challenging and expensive market niches for pharmaceutical
companies. During the process of development and discovery of new
compounds for the CNS, the costs for reaching phase I clinical trials
can go up to US$100 million and around US$1 billion before reaching
the consumer [37]. Taking into consideration these numbers it is of ut-
most importance to be effective in the development phase. However,
in recent years, only a minor number of brain-directed pharmaceuticals
have reached the market (3–5%) since most of them were incapable of
crossing the BBB in vivo [38]. Currently, advances in the ﬁeld of
nanomedicine have generated several platforms that improve drug
transport across the BBB, namely NPs [39–42]. In this review, we will
cover NPs used to transport drugs through the BBB when administered
intravenously as well as the factors that inﬂuence its transportation.
NPs are colloidal carriers that can have a natural or synthetic origin
and can vary from1 to 1000nm in size. There are other types of colloidal
carriers, for example liposomes andmicelles that have been extensively
studied for drug delivery to the brain. Since they possess unique fea-
tures that distinguish them from polymeric and inorganic NPs, this
issue will not be covered in this review.
Synthetic NPs may be prepared from polymeric materials
such as poly(ethylenimine) (PEI), poly(alkylcyanoacrylates),
poly(amidoamine) dendrimers (PAMAM), poly(ε-caprolactone) (PCL),
poly(lactic-co-glycolic acid) (PLGA), polyesters (poly(lactic acid)
(PLA), or from inorganic materials such as gold, silicon dioxide (silica),
among others (Fig. 3). These carriers can transport drugs by adsorbing,
entrapping or bounding covalently to them [43–45]. Inorganic NPs offer
advantages over polymeric NPs in terms of control over size and shape
and simplicity of preparation and functionalization. Most importantly,inorganic NPs are easier to track by microscopy techniques
(e.g. magnetic resonance imaging (MRI), TEM) or analytic techniques
(e.g. ICP-MS). However, inorganic NPs also have disadvantages because
they might not be degraded (or eliminated through the kidneys) or
present undesired toxicity (e.g. carbon nanotubes and fullerenes may
lead to lipid peroxidation and oxygen radical formation). On the other
hand, natural NPs are produced from natural polymers, such as
polysaccharides (chitosan and alginate), amino acids (poly(lysine),
poly(aspartic acid) (PASA)), or proteins (gelatin and albumin) [36,46].
Natural NPs have the advantage of providing biological signals to inter-
act with speciﬁc receptors/transporters expressed by endothelial cells
but they have the disadvantage of batch-to-batch variability, limited
ability for controlled modiﬁcation and poor tracking capacity by imag-
ing platforms (Fig. 3).
The physico-chemical properties of NPs determinewhich is the pas-
sage mechanism across the BBB. The following transport mechanisms
have been described (Fig. 2): (i) NPs open TJs between endothelial
cells or induce local toxic effects which leads to a localized perme-
abilization of the BBB allowing the penetration of the drug in a free
formor conjugatedwith theNPs [21,47]; (ii) NPs pass through endothe-
lial cell by transcytosis [48]; (iii) NPs are transported through endothe-
lial cells by endocytosis, their content is released into the cell cytoplasm
and then exocytosed in the endothelium abluminal side [49]; or (iv) a
combination of several of the mechanisms described previously.
According to some studies, mechanisms ii, iii and iv are the main trans-
portmechanisms of NPs. In case ofmechanism ii, several receptors have
been targeted by NPs including transferrin [50] and low-density lipo-
protein receptors [51,52]. The targeting has been achieved by peptides
[51,53], proteins [52] or antibodies [50] physically or chemically
immobilized on top of the NPs.
NPs are exciting systems for brain drug delivery due to the possibil-
ity to modulate them in terms of shape, size, hydrophobicity, coating,
chemistry and surface charge. Control over these features can enhance
the ability of NPs to improve the therapeutic agent stability in circula-
tion, to control the cargo release into the desired target site, to enhance
BBB penetration efﬁciency and to escape the reticuloendothelial system
[39,44,45]. These features will be discussed in the next section and are
summarized in Fig. 3.
5.1. Factors that inﬂuence the passage of NPs across the BBB
There are several parameters that affect the efﬁciency of NP systemic
circulation, BBB passage and cellular delivery. Several studies have been
shown a clear inverse correlation among NP size and BBB penetration
[30,54,55] (Fig. 3). In particular, most of the studies performed so far
with stroke, AD or PD animal models have used NPs with diameters be-
tween 50 nm to 100 nm (see below Section 6). The shape of NPs also in-
ﬂuences body distribution and cellular uptake [22]. The shape of NPs
can vary from spherical, cubic, rod-like, among other forms (Fig. 3).
Most of the studies have been performed with spherical NPs since
they are relatively easy to prepare. Although, in vitro studies have also
demonstrated that nanorods coated with speciﬁc antibodies have
higher adhesion propensity than their spherical counterparts. Speciﬁ-
cally, polysterene NPs with a rod shape (501 ± 43.6 × 123.6 ±
13.3 nm) coated with an antibody against the transferrin receptor
showed in vivo a 7-fold increase in brain accumulationwhen compared
to their spherical NP counterpart (200± 0.01 nm) [56]. Zeta potential is
another important parameter that affects the passage of NPs through
the BBB. It has been shown that NPs with high zeta potential (high
positive charge) cause immediate toxicity to the BBB [57]. Therefore,
most of the NP formulations described in the literature for brain
delivery have moderate (between −1 to −15 mV) [35,47,48,58] or
high (between−15 to−45 mV) [22,59] negative zeta potentials. Yet,
some NP formulations with moderate (up to 15 mV) or high positive
zeta potential (above 15 mV) have been able to cross the BBB and in
some cases are efﬁcient brain delivery systems (Fig. 3) [21,60].
Fig. 3.Main nanoparticle (NP) features inﬂuencing systemic delivery and blood brain barrier (BBB) passage. NPs can be classiﬁed into natural, whenmolecules such as proteins (albumin),
polysaccharides, chitosan, among others are used, or synthetic. Synthetic NPs can be made of very common polymers such as poly(lactic-co-glycolic acid) (PLGA), poly(ethylenimine)
(PEI), polyesters (poly(lactic acid) (PLA), or from inorganic agents like gold, silica or alumina. NPs can vary in their size (1–1000 nm) and are able to deliver drugs into cells by
entrapping, adsorbing or covalently bounding them. NPs can assume different shapes (spherical, cubic, and rod-like) and charges (negative, zwitterionic, and positive); negatively
charged spheres are widely used in intravenous applications. Another important feature of NPs is the possibility of functionalization with different types of ligands. Ligands are
distributed into four major categories: i) capable of mediating protein adsorption (e.g. poly(sorbate) 80 (P-80)); ii) able to interact directly with the BBB (e.g. transferrin proteins,
antibody or peptides); iii) capable of increasing hydrophobicity (e.g. amphiphilic peptides); and iv) able to improve blood circulation (e.g. poly(ethylene glycol) (PEG)).
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penetration. Such molecules can be grouped into four different types
(Fig. 3): (i) ligands that mediate the adsorption of proteins from the
bloodstream that interact directly with BBB receptors or transporters
[61]; (ii) ligands that have direct interaction per se with BBB receptors
or transporters [20,31,48], (iii) ligands that increase charge and hydro-
phobicity [32] and (iv) ligands that improve blood circulation time
(e.g. PEG) [47]. In the ﬁrst case, we can include poly(sorbate 80) (also
known as Tween 80) that can adsorb apolipoprotein E and/or A-I. The
surfactant allows the anchoring of apolipoproteins whose interaction
with lipoprotein receptors expressed in the brain endothelium enables
the crossing of the BBB. In the second case, we can include several
targeting ligands such as the ones for transferrin receptor (transferrin
peptide, transferrin protein or antibody against transferrin) [48,62,63],
insulin receptor [31,64], glucose transporter [20], among others
(Fig. 2). In the third case, NPs have been coated with amphiphilic pep-
tides to facilitate the uptake by BBB endothelial cells. In addition, the
number of ligands as well as their receptor afﬁnity has an important
impact in the transport of NPs across the BBB (avidity). Ligand density
depends on both the NP surface area and the ligand size. Typically, the
ligand afﬁnity to its receptor is reduced when conjugated to NPs. NP
avidity and selectivity increases when multiple targeting ligands are
conjugated [47,65]. However, NP avidity must be modulated for effec-
tive BBB transcytosis. High avidity will impede NPs bound to the recep-
tor to be released into the brain parenchyma. It has been shown that
gold NPs conjugated with high concentrations of transferrin (100–200
molecules of transferrin per NP) stay bound to brain endothelial cells.
In contrast, gold NPs conjugated with low concentrations of transferrin
(20–30molecules of transferrin perNP) can interact effectively with the
receptor, undergo transcytosis and be released into brain parenchyma
[48].
When NPs enter a physiological environment there is a rapid ad-
sorption of proteins from the bloodstream to the NP surface forming a
protein coating — the “protein corona” [66,67]. Over 70 different
serum proteins have been reported to adsorb to the surface of gold
NPs [66]. The protein corona may alter the surface chemistry of the
NPs along with its aggregation state. Very often it also acceleratesblood clearance of theNPs through the reticuloendothelial system local-
ized mostly in the spleen and liver [39,68], which may decrease the NP
dose available for accumulation in the brain aswell as induce inﬂamma-
tion. The most common way to overcome this issue is to use molecules
with the capacity to minimize surface fouling in order to maintain per-
formance and safety of materials. In this sense, antifouling properties
can be enhanced by using PEG-coated NPs. PEGylated NPs presentmin-
imal surface charge leading to lower NP opsonization and lower reticu-
loendothelial system uptake [69]. Grafting NPs with PEG (5 kDa;
between 0.16 and 0.64 PEG molecules per nm2) decreases protein ad-
sorption and slows down the clearance of the nanomaterials [66,70].
Moreover, due to its improved blood circulation time, PEGylatedNPs ac-
cumulatemore efﬁciently in the brain [65,71]. For instance, polystyrene
NPs (below 200 nm) coated with PEG (5 kDa; 9 PEG molecules
per 100 nm2) are able to cross the BBB. Additionally, PLGA NPs
(ca. 78 nm) coated with PEG are also able to rapidly penetrate rat
brain tissue ex vivo, in contrast with uncoated NPs [71].
In summary, several parameters inﬂuence the transport of NPs
through the BBB at different extents. The characterization of the NP is
highly variable and some aspects such as ligand density and its impact
in NP transport through the BBB are not well studied. So far, NPs conju-
gatedwith ligands able to interact with BBB receptors at a relatively low
density (low avidity) have the best performance. Yet, it is important to
note that the best formulations administered intravenously deliver up
to 5%of the initial dose effectively across the brain. NP brain delivery im-
provementmight require systems that target and cross more efﬁciently
the BBB but also systems that are slowly clear from the bloodstream. Re-
garding this last issue, the charge and the morphology of the NP have a
very important effect in the clearance. Neutral and zwitterionic NPs
have a longer circulation time after intravenous administration, in
contrast to negatively and positively charged NPs [72]. In addition,
short-rod NPs are preferentially retained in the liver and present a
rapid clearance rate, while long-rod NPs are caught in the spleen and
have a lower clearance rate. If the surface is modiﬁed with PEG, reten-
tion increases in lung for both formulations [58]. In the section below
we discuss how NP parameters inﬂuence the targeting and transport
of the NPs across the BBB in animal models of stroke, AD and PD.
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brain diseases
The BBB is responsible for brain homeostasis and protection. Impair-
ment of this structure, observed in neurodegenerative disorders, leads
to inﬂammation perpetuation and neurodegeneration (Fig. 1) [2]. In
some cases, it is clear that BBB breakdown is a consequence of a speciﬁc
event such as traumatic brain injury or ischemic stroke [73]. In other
cases, especially in chronic neurodegenerative conditions like AD and
PD, it remains unclear if it is a downstream process or if it plays a role
in disease onset and development [74,75]. Importantly, these modiﬁca-
tions should be considered as an opportunity to design more efﬁcient
delivery systems and launch novel promising noninvasive therapeutic
approaches for brain disorders. In the next sections, we will review
the most relevant NP-related delivery systems in vivo that can be
administered intravenously and have promising functional recovery
outcomes in stroke, AD and PD pathologies (Figs. 4B, 5B, 6B).
6.1. Stroke
6.1.1. BBB alterations
Stroke is themost costly and long term disabling condition in adult-
hood worldwide affecting approximately 800,000 people per year [3].
During a stroke episode the brain is deprived of blood supply, by aFig. 4. Schematic representation of themain event causing ischemic stroke and summary of them
stroke. A) Ischemic stroke occurs when there is a blood ﬂow interruption caused by a clot cul
neurodegeneration. B) Description of the therapeutic approaches and main conclusions obtainbleeding vessel (hemorrhagic stroke) or by occlusion of a vessel due
to a blood clot (ischemic stroke) (Fig. 4A) [76]. In both cases there is a
deprivation of oxygen and nutrients, resulting in brain cell death that
can culminate in the loss of neurological functions and ultimately in
patient death.
The development of several animal models of stroke [77] was
essential to shed light into the cellular and molecular mechanisms
that occur in a stroke episode. The middle cerebral artery occlusion
(MCAO)model, that can be transient or permanent, is the gold standard
for the brain ischemic animal models of stroke. Nevertheless, other
models such as the photothrombosis model are starting to be more
widely used due to its less invasiveness and high reproducibility.
During the ischemic stroke the BBB opens for a short period
(minutes to hours), followed by a refractory interval and then, it re-
opens for an extended time (hours to days) [78–80]. The restitution of
the blood supply (reperfusion) is essential to limit cerebral injury, but
this process can also exacerbate damage (appropriately termed reperfu-
sion injury). Speciﬁcally, it contributes to the latter reopening of BBB
which is attributed to endothelium activation, ROS production, leuko-
cyte recruitment, cytokine production and edema formation [73,81].
BBB dysfunction developed during ischemic stroke is mainly associated
with loss and disruption of TJs [82]. TJs are degraded bymatrix metallo-
proteinases (MMPs), which are widely involved in tissue remodeling
[79,83]. MMPs also contribute to BBB extracellular matrix degradation,ost promising nanoparticle (NP)-based strategies used in pre-clinical studies for ischemic
minating in oxygen and nutrient depletion and consequently in neuroinﬂammation and
ed in studies using intravenously-administered NPs in stroke pre-clinical models.
Fig. 5.Main pathologic hallmarks found in Alzheimer's disease (AD) brain and nanoparticle (NP) delivery systems used in pre-clinical animal models of AD. A) Themain characteristics of
AD are the presence of amyloid plaques and neurobribrillary tangles in neurons, which culminates in severe neurodegeneration, shrinkage of the cerebral cortices and hippocampus, and
enlargement of the ventricles. B) Description of the therapeutic approaches and main conclusions obtained in studies using intravenously-administered NPs in pre-clinical models of AD.
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particular, increased levels of MMP-9 are correlated with higher BBB
permeability and disease severity in strokepatients and in stroke animal
models [85,86]. In turn, in ischemia reperfusion the increased levels of
nitric oxide (NO) activate MMP-9 and MMP-2 promoting a leaky BBB
[87]. MMP activity may also be stimulated by vascular endothelial
growth factor (VEGF), an angiogenic factor. Accordingly, endothelial
cells treated with VEGF showed reduction in both transepithelial
electrical resistance and claudin-5 and occluding expression, while in
vivo inhibitors of VEGFwere able to reduce BBBpermeability and infarct
volume in hypoxia models [88].
The inﬂammatory response, particularly through the activation of
microglial cells and inﬁltration and activation of peripheral leukocytes
is also responsible for BBB breakdown and cell death upon stroke [89].
Microglia, the brain's ﬁrst line of defense, become activated and
release NO and produce ROS, cytokines (e.g. tumor necrosis factor-
alpha (TNF)-α, interleukin-1beta (IL-1β) and IL-6) and chemokines
(e.g. macrophage inﬂammatory proteins-1alpha (MIP-1α)/CCL3,
monocyte chemoattractant protein-1 (MCP-1)/CCL-2 and chemokine
(C-X-C motif) ligand-1 (CXCL-1)). These inﬂammatory modulators
stimulate endothelial cells and activate the nuclear factor (NF)-kB path-
way promoting the expression of adhesion molecules such as vascular
cell adhesion protein (VCAM), intercellular adhesion molecule-1
(ICAM-1) andP-selectin [89]. These events culminate in the recruitmentand brain parenchyma invasion of peripheral leukocytes enhancing and
perpetuating the inﬂammatory cascade [90].
Drug delivery in cases of stroke should take into consideration that
TJs are compromised and that there is an initial and late opening of
the BBB. The leaky BBB and/or the expression of some receptors onto
the luminal side of endothelial cells may stand for an opportunity to in-
crease the rates of NPs bypassing the BBB. As so, BBB can be by itself a
promising target for improving drug delivery into the ischemic brain.
6.1.2. BBB-permeable NPs for stroke therapy
To overcome stroke-induced neuronal tissue damage, NPs have been
used to deliver neuroprotective drugs that in their free form cannot pass
the BBB, or do so in very low amounts, and are rapidly cleared by the re-
ticuloendothelial system [91]. For example, chitosan NPs (with a diam-
eter of ca. 650 nm; Zeta potential:+20mV) conjugatedwith transferrin
receptor antibody and loaded with a speciﬁc caspase-3 inhibitor (Z-
DEVD-FMK), showed promising results. This formulation was able to
cross the BBB (peak levels after 75 min), and decreased infarct volume
(between 40 and 45%) and neurological deﬁcits induced by ischemia
in aMCAOmicemodel of stroke. It was also able to reduce caspase-3 ac-
tivity [36]. Moreover, these NPswere able to further decrease the infarct
volume and to improve themotor function deﬁcit scores of MCAOmice
when loadedwith both Z-DEVD-FMK and basic ﬁbroblast growth factor
(bFGF) providing a 3 h therapeutic window [50]. Besides bFGF and Z-
Fig. 6. Parkinson's disease (PD) hallmarks and nanoparticle (NP) delivery systems used in pre-clinical animalmodels of PD. A) The PD brain is characterized by a selective loss of substantia
nigra dopaminergic neurons culminating in striatal dopamine depletion due to the degeneration of dopaminergic nigrostriatal pathway. B) Summary of the most relevant therapeutic
approaches used in pre-clinical studies of PD based in a systemic delivery of NPs.
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protection and neuroregeneration. Tanshinone IIA, a phenanthrene-
quinone derivative, has been proposed as a promising drug against
oxidative stress in neurological disorders, namely in the prevention of
ischemic injury [92,93], however, like many other molecules, it has a
short half-life in circulation, poor solubility and low BBB permeation
[94]. To overcome these limitations, cationic bovine serum albumin-
conjugated tanshinone IIA PEGylated NPs (with a diameter of ca.
118 nm; Zeta potential: −18 mV) were developed and injected in a
MCAO rat model. This approach resulted in ameliorated infarct volume
(decrease of approximately 70%), reduced neurological deﬁcit, neutro-
phil inﬁltration and neuronal apoptosis after an intravenous injection
at the time of reperfusion. Moreover, these NPs induced neuroprotec-
tive effects through themodulation of inﬂammatory processes and neu-
ronal signaling pathways, by down-regulating pro-inﬂammatory
cytokines, like IL-8 and TNF-α and up-regulating anti-inﬂammatory cy-
tokines, such as IL-10 and transforming growth factor-β1 (TGF-β1) in
the rat ischemic brain. NP administration also resulted in lower mRNA
and protein levels of glial ﬁbrillary acidic protein (GFAP), MMP-9,
ciclo-oxigenase-2 (COX-2) and inducible nitric oxide synthase (iNOS).
Reduced mRNA and protein phosphorylation levels of p38 mitogen-
activated protein kinase (p38MAPK), c-Jun N-terminal kinase (JNK)
and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2)were also observed [95,96]. Another molecule with a signiﬁcant poten-
tial for neuroprotection is adenosine [97]. However, the inability to
cross the BBB together with moderate toxicity and short half-life
[98,99] hamper the brain delivery of adenosine per se. To bypass these
limitations an injectable NP formulation (with a diameter of 120 nm;
Zeta potential: −25 mV) obtained by the conjugation of adenosine
with squalene was developed [100]. Injection of this formulation prior
to stroke-induction by MCAO decreased the infarct area and enhanced




AD affects over 5 million people only in the USA and it is the major
cause of dementiaworldwide [4]. Themain characteristic of AD ismem-
ory loss. Brain atrophy, accumulation of amyloid-beta peptide (Aβ)
(senile plaques), presence of hyperphosphorylated tau ﬁlaments
(neuroﬁbrillary tangles) and cerebrovascular changes that culminate
in cerebral amyloid angiopathy (CAA) are hallmarks of the pathology
(Fig. 5A) [75,101].
Currently, none of the available animalmodels truly replicate the AD
neuropathology spectrum. Nevertheless, transgenic models have been
42 C. Saraiva et al. / Journal of Controlled Release 235 (2016) 34–47of great value to better understand the pathology although they rely on
mutations from early-onset familial forms of human AD (5% of the AD
total cases). Rodents models infused with Aβ sequences are also highly
used for understanding the physiopathology of AD and drug develop-
ment due to their simplicity and affordability. Many other AD animal
models have been developed over the years [102].
BBB dysfunction in AD has been investigated in the past decades and
remains a controversial subject among the scientiﬁc community [103].
Several studies conducted in both AD patients and in AD animal models
suggest that cerebrovascular alterations result from the accumulation of
Aβ peptide [104–106]. In healthy conditions, P-glycoprotein (P-gp) and
low-density lipoprotein receptor-related protein (LRP) are responsible
for Aβ clearancewhile the receptor for advanced glycation endproducts
(RAGE) controls the Aβ inﬂux to the brain [107]. Importantly, higher
amounts of Aβ found in AD induce upregulation of RAGE expression,
generating a positive feedback loop which further exacerbates brain ac-
cumulation of Aβ and also activates several inﬂammatory and oxidative
cascades [108]. Aβ-RAGE interaction also triggers TJ disruption via
intracellular Ca2+-calcineurin signaling and MMP-2 and -9 secretion
[109,110]. Moreover, mice deﬁcient in apolipoprotein isoform 4
(ApoE4), the main genetic risk factor for the development of sporadic
AD, present vascular atrophy and higher levels of RAGE [111], which
culminate in reduced Aβ clearance and a compromised BBB [112].
A reduced activity of efﬂux transporters of BBB endothelial cells,
located on the apical side, may also account for Aβ accumulation in
the brain parenchyma. In particular, downregulation of LRP [113] as
well as a decreased activity of P-gp [114] were reported in patients
and AD animal models, further strengthening this hypothesis. Microglia
and astrocytes are also main players in controlling the levels of Aβ
load and boosting Aβ production when activated [115]. Moreover, se-
cretion of TNF-α by activated microglia enhances the adhesion and
transendothelial migration of T cells [116]. In parallel with Aβ-induced
toxicity, these events activate a cycle of inﬂammation and continuous
tissue damage.
Another line of research suggests the dysfunction of the BBB as the
cause of neurodegeneration. In mouse models of AD, BBB impairment
was observed before Aβ accumulation [117]. Similarly, AD patients
also showed diminished blood ﬂow and glucose uptake by the BBB
prior to brain atrophy and neurodegenerative changes [118]. This
impaired metabolic demand may be associated with decreased
GLUT-1 expression [119,120].
Overall, both hypotheses consider tauopathies as a secondary event.
However, it was shown that tau alone is able to initiate BBB breakdown
and its downregulation promotes recovery of BBB integrity in a trans-
genic mouse model [121].
6.2.2. BBB-permeable NPs for AD therapy
The search for newdrug candidates to ﬁght AD pathology has shown
that neuroprotective peptides may be a good investment therapy-wise.
They can act in a variety of ways by breaking down Aβ plaque forma-
tion, degrading Aβ toxic peptide and modulating some enzymes as
secretases. For instance, PEG-PLA NPs (with a diameter of ca. 120 nm;
Zeta potential:−23mV)modiﬁedwith B6 peptide (a transferrin substi-
tute) and loaded with the neuroprotective peptide NAPVSIPQ (NAP)
were able to accumulate in the brain of mice (peak levels between 0.5
and 12 h) compared to NPs without B6. Peripheral accumulation of
both formulations was found in the liver, lung and spleen with higher
levels of accumulation for NPs without B6. The administration of the
B6/NAP PEG-PLA formulation in a mouse model of AD, obtained by
bilateral stereotaxic injection of Aβ1–40, ameliorated spatial learning
deﬁcit and improved cholinergic function, likely due to a decrease of
acetylcholinesterase (acetylcholine degrading enzyme) and an increase
of choline acetyltransferase (acetylcholine synthesizing enzyme) activ-
ity [122]. Another molecule of interest for brain-targeted therapies is
the nerve growth factor (NGF). In the basal forebrain this molecule is
vital for central cholinergic neuron survival. However, NGF is not ableto cross the BBB rendering a major obstacle for its use in noninvasive
AD therapy. NGF adsorbed on PBCA nanoparticles coated with polysor-
bate 80 (with a diameter of ca. 250 nm) was administered in outbred
C57BL/6 mice and reached the brain parenchyma in signiﬁcantly higher
amounts at 45 min after administration. Its therapeutic potential in
age-related neurodegenerative disorders was shown by the ability to
reverse amnesia in an acute scopolamine-induced amnesia model (a
proposed paradigm for AD) and to improve recognition and memory
as well as to reduce some PD symptoms (rigidity, oligokinesia and
tremor) by approximately 40% in a 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced model of PD [123].
Coenzyme Q10, the prevalent form of coenzyme Q in humans, is a
cofactor involved in mitochondrial oxidative phosphorylation cascade,
acting as a powerful antioxidant. There is, therefore, a strong rationale
for its therapeutic use in several neurodegenerative diseases, including
AD. In this sense, coenzyme Q10-loaded PLGA NPs modiﬁed with
trimethylated chitosan (with a diameter of ca. 150 nm; Zeta potential:
+20 mV) were able to improve cognitive and spatial memory perfor-
mances in an APP/PS1 transgenic mouse model of AD. A relevant brain
uptake of this formulation was observed in the ventricles, choroid plex-
us and cortex, probably due to adsorptive-mediated transcytosis. No
brain uptake was observed when void NPs were used. Moreover, a re-
duction of senile plaques and oxidative stress levels obtained by assays
usingmalondialdehyde (MDA), glutathione (GSH)-peroxydase and cat-
alase activity was also demonstrated with trimethylated PLGA NPs,
proving the potential of this formulation as a new AD therapeutic strat-
egy [124].
NPs can be used not only as vehicles to deliver therapeutic agents
but also as imaging agents, or both. These so called theranostic agents
confer diagnosis and therapy and normally take advantage of nanosys-
tems that are by themselves imaging agents, such as iron oxide, gold
and silica NPs, carbon nanotubes and quantum dots [125]. Polymeric
n-butyl-2-cyanoacrylate (BCA) NPs encapsulated with radio-labeled
125I-clioquinol (CQ, an amyloid afﬁnity drug) and coated with 1%
Tween 80 surfactant (with a diameter of ca. 50 nm) revealed to be
promising for AD diagnosis. These NPs showed high afﬁnity for Aβ
plaques in vitro and in vivo, being also able to label Aβ plaques from
frontal cortical sections of AD human post-mortem tissue.125I-CQ-
PBCA NPs were able to penetrate the brain parenchyma and its reten-
tion was signiﬁcantly higher in two AD mouse models, the APP/PS1
transgenic mice and mice injected with aggregated Aβ42 peptide,
than in healthy controls. 125I-CQ-PBCA NP brain uptake and retention
in AD mouse brain was also higher than that observed with free 125I-
CQ with a peak at 90 min after administration. Therefore, radiolabeled
CQ-PBCA NPs can possibly be used as a promising carrier and amyloid
imaging agent in vivo using non-invasive methods, single photon emis-
sion tomography (SPECT) (123I) or PET (124I) [126]. A summary of the
abovementioned strategies is found in Fig. 5B.6.3. Parkinson's disease
6.3.1. BBB modiﬁcations
PD is a neurodegenerative disease that affects approximately
10 million people throughout the world [5]. PD is characterized not
only by the selective degeneration of dopaminergic neurons in the
substantia nigra (SN) that culminates in the depletion of dopamine
(DA) in the striatum (Fig. 6A), but also by the existence of α-synuclein
and protein inclusions in neurons termed Lewy bodies [127].
PD models are based on the administration of toxins such
as 6-hydroxidopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), rotenone, paraquat, to name a few, that
cause the selective death of dopaminergic neurons. Genetic models
are highly used to modeling familial PD, but have also been essential
to shed some light on more common PD mechanisms. These animal
models and others are intensively discussed in Jamag et al. [128].
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ment [129]. However, studies tracking drugs like benzerazide and [11C]
verapamil, unable to cross BBB in normal situations, demonstrated that
these drugs were increased in the brain of PD patients and rat PD
models, likely due to the reduction of P-gp expression levels [130].
The albumin ratios in the brain of PD patients and age-matched controls
also showed a correlation between the pathology course and the pro-
gressive BBB impairment [131]. Cerebral blood ﬂow deﬁciencies and
vascular alterations associated to BBB integrity loss were also found in
striatum and SN of patients with PD [132–134]. A higher amount of
blood vessels in the periphery of damaged dopaminergic neurons in
the SN of monkeys was correlated with an increase in VEGF expression
[135]. VEGF injected into the SN of rats was also able to disrupt the BBB
and resulted in a consequent loss of dopaminergic neurons and strong
inﬂammation [136]. Similarly to what was previously stated regarding
AD, MMP activation is also essential in PD-associated BBB breakdown.
In particular, MMP-3 promotes dopaminergic degeneration, barrier im-
pairment and immune cell inﬁltration into the brain of MPTP-intoxicat-
ed mice [137].
Inﬂammatory events including microgliosis, astrocytosis and inﬁl-
tration of T-leukocytes found in the midbrain of PD patients and rat
models are also intimately related with dopaminergic neuronal loss
and BBB permeability [138–141]. A higher release of pro-inﬂammatory
cytokines (TNF-α, IL-1β and interferon-γ) and the production of ROS
and NO by activated astrocytes and microglia, during PD, is associated
with BBB impairment [141–143].
Αlpha-synuclein deposition is one of the causes of PD and downreg-
ulation of the P-gp may contribute to α-synuclein brain accumulation
[144]. Of note, deposition of α-synuclein promotes an increase in BBB
dysfunction in mice injected with lipopolysaccharide [145]. In addition,
increased content of metals like iron andmanganese were also found in
brain lesioned regions in PD patients and animal models [146]. In fact,
lactoferrin receptor levels are increased in SN dopaminergic neurons
of both animal models and PD patients and are potentially implicated
in neuronal iron uptake contributing to dopaminergic neuronal degen-
eration. The upregulation of lactoferrin receptors was also found on the
blood–brain vasculature and was correlated with BBB changes in PD
[147–149]. Therefore, it is of the utmost importance to understand
whether hallmarks of PD pathogenesis can be responsible for triggering
vascular impairment to streamline the most effective BBB-directed
therapy for PD. One example would be taking advantage of lactoferrin
receptors not only as a way to improve drug loaded NP uptake into
the brain but also as a therapeutic target in order to reduce the disease's
progression.6.3.2. BBB-permeable NPs for PD therapy
Dopamine replacement therapies are currently the most used forms
of PD treatment, since they are able to improve motor symptoms. Nev-
ertheless, effects on behavior and cognition are still controversial [150].
In line with this, Pahuja and colleagues have developed dopamine-
loaded PLGA nanoparticles (DA NPs) (with a diameter of ca. 120 nm;
Zeta potential: −3 mV) that were able to improve animal behavior,
namely by reducing amphetamine-induced rotation, without showing
any signs of heart-related alterations or abrupt changes in the brain or
in the periphery. DA NPs were able to cross the BBB mainly in the SN
and striatum (PD-altered regions) of 6-hydroxydopamine (6-OHDA)
rats and their presence near and inside neurons and astrocytes was
also conﬁrmed. Moreover, a slow and controlled release of DA by NPs
as well as a reduced plasma clearance and autoxidation were detected
6 h after injection. DA NPs also increased the levels of DA and its
metabolites homovanillic acid (HVA) and dihydroxyphenylacetic acid
(DOPAC) almost to levels similar to control mice while reducing
dopamine-D2 receptor hypersensitivity to control levels. In conclusion,
this study shows that DANPs can prevent toxicity associated to bulk do-
pamine and can provide a novel strategy to ﬁght PD [151].As discussed previously, increased expression of lactoferrin and its
receptors in the SN and striatal dopaminergic neurons and BBB endo-
thelial cells of PD patients [147,148], the most susceptible regions for
dopaminergic degeneration, may aid the speciﬁc uptake of NPs at le-
sioned regions. This suggests that the delivery system efﬁcacy under
PD conditions might be enhanced by attaching lactoferrin to NPs. More-
over, lactoferrin may protect and exert an antioxidative effect on dopa-
minergic neurons by chelating the increased levels of iron present in the
SN and striatumof PDpatients and animalmodels [152,153], suggesting
that lactoferrin may have a dual effect, acting as a ligand to promote re-
ceptor-mediated BBB transcytosis in the lesioned dopaminergic regions
and by inducing repair of the same regions. It was further demonstrated
that lactoferrin has higher uptake efﬁcacy compared to transferrin and
OX-26 (an anti-transferrin-receptor antibody) (with a diameter of ca.
158/159 nm; Zeta potential:−11/−9 mV, respectively) [154]. Based
on these assumptions, Huang and collaborators developed a PAMAM
and PEG NP (with a diameter of ca. 200 nm; Zeta potential: +30 mV)
modiﬁed by lactoferrin and loaded with a plasmid for the human glial
cell line-derived neurotrophic factor gene (hGDNF). GDNF is considered
the golden standard neurotrophic factor for PD therapy but it is unable
to cross the BBB. This nanoformulation functionalized to deliver GDNF
was able to cross the BBB and exert a neuroprotective effect on dopami-
nergic neurons as well as an improvement of the locomotor activity in
both experimental protocols. Yet, these effects were more robust
when the formulation was administered more than once. In addition,
functional dopaminergic recovery was achieved as shown by the in-
creased levels of monoamine neurotransmitters in both the 6-OHDA
and rotenone-induced PD rat models [155,156].
Urocortin, a corticotrophin releasing hormone-related peptide, is
also a promising target to protect dopaminergic neurons but it is unable
to cross the BBB like many other molecules. PEG-PLGA NPs functional-
ized with lactoferrin (with a diameter of ca. 90 nm; Zeta potential:
−24mV) for the delivery of urocortin to the brainwere found in cortex,
SN and striatum regions 1 h after injectionwhile NPswithout lactoferrin
were barely observed. This formulation was able to protect dopaminer-
gic neurons, improve locomotor functional deﬁcits (evaluated by the
apomorphine-induced rotation test) and increase the levels of DA and
its metabolites HVA and DOPACwithout an excessive toxicity (detected
by cluster of differentiation (CD)68 immunoreactivity) [157]. These NP-
based delivery strategies for PD are summarized in Fig. 6B.
7. Future prospects
The BBB is very important in the maintenance of CNS normal func-
tion and its disruption is related with progression of several brain pa-
thologies. Understanding the mechanism(s) underlying its regulation
in the healthy and disease brain is essential to a better knowledge of dis-
ease pathophysiology. Although it remains unclear what causes BBB
dysfunction, either loss of CNS maintenance signals or breakdown sig-
nals from the pathological state, we now have a vast knowledge on
physical and molecular alterations beyond the BBB breakdown in pa-
thology. Taking advantage of the current knowledge on BBB impair-
ment, which is related to higher expression of speciﬁc receptors in
endothelial cells from brain capillaries such as RAGE in AD or lactoferrin
in PD, it is feasible to design a strategy for more effective drug delivery
into the lesioned brain. Nanocarriers are small agents with the capabil-
ity of enclosing drugs conferring themprotection, increasing their circu-
lation time and providing a temporally and spatially controlled release
of their cargo into the lesion site after intravenous injection. Some guid-
ing principles to enhance the transport of NP formulations through the
BBB have been recently recognized. For example, the use of certain li-
gands on the NP surface, ligand density and NP shape, among other as-
pects, have been highly scrutinized in the past decade. In addition, some
of the principles in the recent successes of antibody transport across the
BBB [158–160] might inspire NP bioengineers to design new formula-
tions with enhanced properties. Additionally, an increasing number of
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neurological disorders (e.g. stroke, AD and PD). Further research is nec-
essary to clarify the differences in NP transport in healthy and disease
animalmodels, always bearing inmind the limitations of an experimen-
tal model which cannot fully mimic a given human disease. Although it
is known that BBB properties are substantially altered in PD, AD or
stroke in vivo models, no systematic studies have been performed to
elucidate how NP physico-chemical properties affect NP transport and
brain localization. To the best of our knowledge there is no NP formula-
tion being currently tested in clinical trials for stroke, AD or PD treat-
ment. However, we may speculate that it is only a matter of time
before NPs developed in pre-clinical tests will be evaluated in future
clinical assays.
Addressing safety issues is also very important tomove this research
area to potential clinical therapies. It is important to note that the most
effective NP formulations for brain delivery still accumulate signiﬁcant-
ly in other regions of the body, such as liver, spleen, kidney among other
organs/tissues, before being eliminated. Thus, it is important to design
nanoformulations that only after reaching the brain are remotely trig-
gered to release the drug [161] instead of doing so in other places of
the body. It is expected that future developments in triggerable
nanoformulations will facilitate the clinical translation of NPs in the
area of regenerative medicine. Another important issue that deserves
further investigation is the development of nanoparticles that can target
speciﬁc brain cells. For instance, in the setting of neurodegenerative dis-
orders the targeting to speciﬁc brain cells such as dopaminergic neurons
(main target in PD), microglia (neuroinﬂammation), or neural stem
cells (neuronal repair) might enhance its potential therapeutic value.
In sum, the development of new platforms that are able to exploit
BBB alterations occurring in these disorders, in combinationwith prom-
ising therapeutic and/or imaging agents, is essential to developmore ef-
ﬁcient non-evasive and brain-directed therapies able to reach the clinic.Acknowledgments
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